Eloralintide
Selective Amylin Receptor Agonist | Obesity & Weight Management
On this page
What is Eloralintide?
Eloralintide is an investigational, lab-made peptide developed by a pharmaceutical company that selectively activates one type of amylin receptor (AMY1R). Researchers are studying it in ongoing Phase 2 human clinical trials for metabolic research, with results reported in the clinical literature. It has not been approved by the FDA or any regulatory agency, and research-grade material sold here is intended strictly for laboratory research use, not human use.
Key terms:
Eloralintide is a selective amy1r amylin receptor agonist.
Eloralintide (LY3841136) is a lab-made, once-weekly peptide from Eli Lilly, developed as an obesity drug candidate. It switches on the AMY1R amylin receptor (amylin is a hormone that signals fullness). Cagrilintide hits amylin and calcitonin receptors broadly; eloralintide is 11- to 12-fold more selective for human AMY1R over CTR and AMY3R. Researchers believe that selectivity explains its much better stomach and gut tolerability while keeping strong weight-reduction results. In a 48-week Phase 2 trial (NCT06230523) in 263 adults with obesity, the peptide alone produced average body-weight reductions of 9.5% to 20.1%, depending on dose, versus 0.4% on placebo; the curves had not yet leveled off at week 48. Eli Lilly said it planned to start Phase 3 trials of the peptide alone by the end of 2025, and is testing it with tirzepatide in the ATTAIN Phase 2 program.
Key research areas
- Once-weekly subcutaneous dosing supported by 13-15 day half-life
- Up to 20.1% mean body weight reduction at 48 weeks in Phase 2
- Markedly improved GI tolerability versus non-selective amylin agonists
- Potential combination partner for tirzepatide
Researched dosing
This table reflects the dose-escalation schedules used in eloralintide's Phase 2 clinical trials — research-trial methodology, not personal dosing guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Phase 2 low dose (single agent) | 1 mg weekly | Once weekly | SubQ |
| Phase 2 mid dose | 3 mg weekly | Once weekly | SubQ |
| Phase 2 high dose | 6 mg weekly | Once weekly | SubQ |
| Phase 2 highest dose | 9 mg weekly | Once weekly | SubQ |
| Slow dose escalation (tolerability) | 3 mg → 9 mg over multiple weeks | Once weekly with stepwise escalation | SubQ |
| Combination with tirzepatide (ATTAIN) | Eloralintide + tirzepatide (doses under study) | Once weekly each | SubQ (separate injections) |
Commonly cycled 48 weeks on, 0+ weeks off.
How it works
At the cell level, eloralintide research looks at how this peptide selectively activates one amylin receptor subtype (AMY1R) in the brainstem and hypothalamus to influence satiety signaling — the term below names that receptor-targeting approach.
Subcutaneous injection allows the lipidated, albumin-binding peptide to achieve sustained plasma exposure. Eloralintide selectively activates AMY1R in the brainstem area postrema and hypothalamus, driving satiety and reduced food intake while sparing CTR-mediated GI side effects.
Pharmacokinetics
This chart plots how long a research dose of eloralintide stays active in Phase 2 trial data — its multi-day clearance curve is part of why the ongoing clinical trials use once-weekly dosing.
- Peak
- 100.8 hr
- Half-life
- 338.4 hrs
- Cleared
- ~1690.8 hrs
Briere et al. Mol Metab 2025 (PMID 41109426)
Research applications
This section summarizes the metabolic-research areas that Phase 2 clinical trials have studied for eloralintide; eloralintide remains investigational and is not approved by the FDA or any regulatory agency for any use.
Weight Reduction
Dose-dependent mean body weight reductions of 9.5% (1 mg) to 20.1% (9 mg) at 48 weeks (NCT06230523, N=263). Weight Reduction continued to progress through week 48, suggesting longer Phase 3 trials may show further reduction. Preclinical data show 85% of weight reduction is attributable to fat mass, with significantly less lean mass loss than cagrilintide.
Appetite Control
Selectively activates AMY1R in the brainstem area postrema and hypothalamus, driving satiety and reduced food intake.
Cardiovascular
Cardiometabolic markers including lipids, hsCRP, and blood pressure begin to improve with continued dosing in Phase 2 studies.
Metabolic
Improvements in metabolic health markers observed during Phase 2 trials with continued treatment.
Dosage reference
- Doses used in research
- Phase 2 trials evaluated doses of 1–9 mg weekly.
- Frequency in studies
- Once weekly (supported by 13-15 day half-life)
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Phase 2 onset: appetite suppression within first weeks; meaningful weight reduction by 4-12 weeks; trajectory continuing through 48 weeks
- Storage
- Refrigerated 2-8°C
- Cycle length
- Continuous treatment under investigation; long-term durability data not yet available
- Break between cycles
- Not established; ongoing trials are evaluating long-term continuous dosing
Interactions
This list shows which other metabolic-research peptides are being studied alongside eloralintide, including an ongoing Phase 2 program pairing it with another investigational compound.
Reconstitution & storage
Eloralintide is currently supplied only within Lilly-sponsored clinical trials in unit-of-use presentations — this section reflects that trial handling process, not a commercially available reconstitution procedure.
- Eloralintide is investigational and is supplied to clinical trial sites in unit-of-use presentations per Lilly trial protocol.
- Allow medication to reach room temperature 15-30 minutes.
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Refrigerated 2-8°C, use within Per Lilly trial protocol
Reconstituted: 2-6°C, use within Per trial protocol; not commercially reconstituted outside Lilly-sponsored trials
Open the Eloralintide reconstitution calculatorQuality indicators
This section covers the molecular design features and Phase 2 safety data that characterize eloralintide, along with a caution that any material sold outside sponsored clinical trials has no verified chain of custody or purity testing.
AMY1R-selective design - 11–12× selectivity for human AMY1R over CTR and AMY3R is the molecular feature that differentiates eloralintide from cagrilintide and underlies improved GI tolerability.
Methylene thioacetal stabilization - Replacement of the native amylin disulfide with a methylene thioacetal bridge significantly improves chemical stability and resistance to fibril formation.
Once-weekly pharmacokinetics - Terminal half-life of 310–366 hours (≈13–15 days) provides smooth weekly exposure with low peak-to-trough variability.
Favorable Phase 2 safety profile - Phase 2 reported mild-to-moderate GI events that were dose-related; lower-dose and slower-escalation arms had AE rates similar to placebo.
Investigational status — not commercially available - Eloralintide is in active Phase 2 development with Phase 3 initiation planned by year-end 2025. Material outside Lilly-sponsored trials is not regulated, not verified for identity or purity, and not appropriate for self-administration.
Long-term durability unknown - No data beyond 48 weeks of continuous treatment exists. Effects of treatment discontinuation, weight regain trajectory, and long-term safety remain under investigation.
Research-grade material from gray-market vendors - Unregulated peptide marketplaces selling 'eloralintide' have no verified chain of custody, sequence verification, or purity assays. Lilly has not licensed any research-use formulation.
What to expect
This timeline reflects what Phase 2 trial data reported at each study stage — research context for comparing trial results, not a personal-results promise.
Initial dose escalation; mild GI events (nausea, fatigue) possible, especially at faster escalation rates. Lower-dose arms (1-3 mg) had AE rates similar to placebo.
Early appetite suppression and 3-6% weight reduction apparent; curve steepens with continued dosing.
Continued steady weight reduction across all active arms; cardiometabolic markers (lipids, hsCRP, BP) begin to improve.
Peak weight-reduction trajectory with mean reductions of 9.5-20.1% across dose arms; weight reduction curve not yet plateauing at trial end.
Safety notes
This section covers eloralintide's investigational regulatory status and the safety data reported so far in Phase 2 trials — reference context for researchers, not medical guidance, since eloralintide is not approved for human use outside sponsored trials.
- Eloralintide is investigational and is not approved by FDA or any regulatory agency
- Safety in pregnancy, lactation, pediatric populations, and chronic disease states has not been characterized
- Not approved by FDA or any regulatory agency — investigational use only in sponsored clinical trials
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
9.5%-20.1% mean body weight reduction vs -0.4% placebo in multicenter, double-blind, randomized, placebo-controlled Phase 2 trial. All eloralintide arms met the primary endpoint; weight-reduction trajectories had not plateaued at week 48.
-2.5% (4 mg) and -4.4% (12 mg) body weight at day 29. Terminal half-life 310-366 hours (approximately 13-15 days). Only 2 of 36 participants reported any GI adverse event.
Demonstrated 11-12× selectivity for human AMY1R over CTR and AMY3R; full agonism (Emax >80%) across all amylin receptor subtypes. 85% of weight reduction attributable to fat mass with significantly less lean mass loss than cagrilintide (p=0.0101) and significantly less conditioned taste avoidance (p<0.05).